Skip to main content
. 2020 May 15;17(2):418–432. doi: 10.20892/j.issn.2095-3941.2019.0215

Figure 4.

Figure 4

Bevacizumab upregulates CD105 and activates the TGFβ pathway in different cell lines under hypoxia, which is reversed by anlotinib regardless of the treatment sequence. (A) HUVECs were treated with bevacizumab (100 μg/mL, 24 h) or anlotinib (10 μM, 12 h) following pretreatment with bevacizumab (100 μg/mL, 12 h) under hypoxia. Anlotinib reversed bevacizumab-induced elevation of CD105. (B) Densitometric analysis of CD105 protein levels shown in (A). Data represent mean ± SD, ***P < 0.001, ANOVA. (C, D) MRMECs and bEnd.3 cells were treated with bevacizumab (0, 10, 100 μg/mL, 24 h) or anlotinib (10 μM, 12 h) following pretreatment with bevacizumab (100 μg/mL, 12 h) under hypoxia. Anlotinib reversed bevacizumab-induced elevation of CD105. Bevacizumab additionally enhanced Smad1 and Smad5 expression.